ILMN - Illumina, Inc.
NASDAQ
->
Healthcare
->
Diagnostics & Research
San Diego,
United States
Type: Equity
ILMN price evolution
ILMN
| (in millions $) | 29 Oct 2024 | 30 Jun 2024 | 1 May 2024 | 31 Jan 2024 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $920 | $1108 | $1048 | |
| Short term investments | $74 | $6 | ||
| Net receivables | $699 | $641 | $650 | $734 |
| Inventory | $574 | $561 | $584 | $587 |
| Total current assets | $2373 | $2459 | $2583 | $2609 |
| Long term investments | ||||
| Property, plant & equipment | $1285 | $1319 | $1514 | $1551 |
| Goodwill & intangible assets | $1357 | $5485 | $5538 | |
| Total noncurrent assets | $3622 | $7457 | $7502 | |
| Total investments | $74 | $6 | ||
| Total assets | $6014 | $6081 | $10040 | $10111 |
| Current liabilities | ||||
| Accounts payable | $191 | $199 | $201 | $245 |
| Deferred revenue | ||||
| Short long term debt | $744 | |||
| Total current liabilities | $975 | $2208 | $1474 | $1570 |
| Long term debt | $1988 | $2106 | $1490 | $2176 |
| Total noncurrent liabilities | $2437 | $2832 | $2796 | |
| Total debt | $2850 | $2190 | $2176 | |
| Total liabilities | $3889 | $4645 | $4306 | $4366 |
| Shareholders' equity | ||||
| Retained earnings | -$1428 | -$2133 | -$145 | -$19 |
| Other shareholder equity | $2125 | $14 | $12 | -$1 |
| Total shareholder equity | $1436 | $5734 | $5745 | |
| (in millions $) | 31 Jan 2024 | 1 Feb 2023 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $1048 | $2011 | $1232 | $1810 |
| Short term investments | $6 | $26 | $107 | $1662 |
| Net receivables | $734 | $688 | $648 | $487 |
| Inventory | $587 | $568 | $431 | $372 |
| Total current assets | $2609 | $3561 | $2713 | $4483 |
| Long term investments | $418 | |||
| Property, plant & equipment | $1551 | $1744 | $1696 | $1454 |
| Goodwill & intangible assets | $5538 | $6524 | $10363 | $1039 |
| Total noncurrent assets | $7502 | $8691 | $12504 | $3102 |
| Total investments | $6 | $26 | $107 | $1662 |
| Total assets | $10111 | $12252 | $15217 | $7585 |
| Current liabilities | ||||
| Accounts payable | $245 | $293 | $332 | $192 |
| Deferred revenue | ||||
| Short long term debt | $1248 | $511 | ||
| Total current liabilities | $1570 | $2773 | $1093 | $1244 |
| Long term debt | $2176 | $1487 | $2469 | $1344 |
| Total noncurrent liabilities | $2796 | $2880 | $3384 | $1647 |
| Total debt | $2176 | $3479 | $2469 | $1855 |
| Total liabilities | $4366 | $5653 | $4477 | $2891 |
| Shareholders' equity | ||||
| Retained earnings | -$19 | $1142 | $5485 | $4723 |
| Other shareholder equity | -$1 | $3 | $17 | $2 |
| Total shareholder equity | $5745 | $6599 | $10740 | $4694 |
| (in millions $) | 29 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Jan 2024 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $1080 | $1112 | $1076 | |
| Cost of revenue | $391 | $409 | ||
| Gross Profit | $745 | $721 | $667 | |
| Operating activities | ||||
| Research & development | $325 | $339 | ||
| Selling, general & administrative | $147 | $439 | ||
| Total operating expenses | $517 | $2358 | $778 | |
| Operating income | -$1637 | -$111 | ||
| Income from continuing operations | ||||
| EBIT | -$1956 | -$91 | ||
| Income tax expense | $15 | $12 | $17 | |
| Interest expense | -$8 | $20 | $18 | |
| Net income | ||||
| Net income | $705 | -$1988 | -$126 | |
| Income (for common shares) | -$1988 | -$126 | ||
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 2 Feb 2022 | 31 Dec 2020 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $4504 | $4584 | $3239 | |
| Cost of revenue | $1760 | $1612 | $1036 | |
| Gross Profit | $2744 | $2972 | $2203 | |
| Operating activities | ||||
| Research & development | $1354 | $1321 | $682 | |
| Selling, general & administrative | $1612 | $1297 | $941 | |
| Total operating expenses | $3813 | $7151 | $1623 | |
| Operating income | -$1069 | -$4179 | $580 | |
| Income from continuing operations | ||||
| EBIT | -$1040 | -$4310 | $905 | |
| Income tax expense | $44 | $68 | $200 | |
| Interest expense | $77 | $26 | $49 | |
| Net income | ||||
| Net income | -$1161 | -$4404 | $656 | |
| Income (for common shares) | -$1161 | -$4404 | $656 | |
| (in millions $) | 29 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Net income | -$1988 | -$126 | -$175 | |
| Operating activities | ||||
| Depreciation | $105 | $108 | $109 | |
| Business acquisitions & disposals | -$29 | |||
| Stock-based compensation | $112 | $96 | $94 | |
| Total cash flows from operations | $80 | $77 | $224 | |
| Investing activities | ||||
| Capital expenditures | -$31 | -$36 | -$51 | |
| Investments | -$10 | -$12 | $13 | |
| Total cash flows from investing | -$130 | -$41 | -$48 | -$85 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $36 | |||
| Net borrowings | $744 | |||
| Total cash flows from financing | -$523 | -$226 | $35 | -$27 |
| Effect of exchange rate | $1 | -$1 | -$4 | $9 |
| Change in cash and equivalents | -$179 | -$188 | $60 | $121 |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Net income | -$1161 | -$4404 | $762 | $656 |
| Operating activities | ||||
| Depreciation | $432 | $394 | $251 | $187 |
| Business acquisitions & disposals | -$29 | -$85 | -$2392 | -$230 |
| Stock-based compensation | $380 | $366 | $754 | $194 |
| Total cash flows from operations | $478 | $392 | $545 | $1080 |
| Investing activities | ||||
| Capital expenditures | -$195 | -$286 | -$208 | -$189 |
| Investments | -$6 | -$40 | $1233 | -$135 |
| Total cash flows from investing | -$231 | -$591 | -$1069 | -$554 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $67 | $63 | $60 | -$675 |
| Net borrowings | -$1236 | $991 | $471 | |
| Total cash flows from financing | -$1210 | $1000 | -$51 | -$766 |
| Effect of exchange rate | -$22 | -$3 | $8 | |
| Change in cash and equivalents | -$963 | $779 | -$578 | -$232 |
News
Fundamentals
| Market cap | $19.42B |
|---|---|
| Enterprise value | N/A |
| Shares outstanding | 159.30M |
| Revenue | N/A |
|---|---|
| EBITDA | N/A |
| EBIT | N/A |
| Net Income | N/A |
| Revenue Q/Q | -8.16% |
| Revenue Y/Y | N/A |
| P/E ratio | N/A |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | N/A |
| P/B ratio | N/A |
| Book/Share | N/A |
| Cash/Share | N/A |
| EPS | N/A |
|---|---|
| ROA | N/A |
| ROE | N/A |
| Debt/Equity | 0.76 |
|---|---|
| Net debt/EBITDA | N/A |
| Current ratio | 2.43 |
| Quick ratio | 1.85 |